Enfusion, Inc. (NYSE:ENFN - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $9.94, but opened at $10.80. Enfusion shares last traded at $10.84, with a volume of 702,654 shares.
Analysts Set New Price Targets
Several research firms recently commented on ENFN. William Blair reissued a "market perform" rating on shares of Enfusion in a research note on Monday. Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, Enfusion currently has an average rating of "Hold" and a consensus target price of $10.25.
Get Our Latest Stock Analysis on ENFN
Enfusion Stock Up 8.8 %
The firm's fifty day moving average price is $10.11 and its two-hundred day moving average price is $9.20. The stock has a market capitalization of $1.39 billion, a PE ratio of 270.32, a PEG ratio of 3.98 and a beta of 0.95.
Insider Buying and Selling at Enfusion
In related news, COO Neal Pawar sold 21,801 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the transaction, the chief financial officer now owns 270,503 shares of the company's stock, valued at approximately $2,870,036.83. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,404 shares of company stock valued at $580,130. Insiders own 36.44% of the company's stock.
Hedge Funds Weigh In On Enfusion
Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in shares of Enfusion by 29.4% in the second quarter. Bank of New York Mellon Corp now owns 159,555 shares of the company's stock valued at $1,359,000 after acquiring an additional 36,257 shares during the period. Rhumbline Advisers raised its stake in shares of Enfusion by 30.3% in the second quarter. Rhumbline Advisers now owns 59,435 shares of the company's stock valued at $506,000 after acquiring an additional 13,832 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Enfusion in the second quarter valued at $183,000. Arizona State Retirement System purchased a new stake in shares of Enfusion in the second quarter valued at $86,000. Finally, American Century Companies Inc. raised its stake in shares of Enfusion by 17.1% in the second quarter. American Century Companies Inc. now owns 35,897 shares of the company's stock valued at $306,000 after acquiring an additional 5,253 shares during the period. Institutional investors own 81.05% of the company's stock.
About Enfusion
(
Get Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
